Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Estrella Immunopharma, Inc. - Common Stock (NQ:ESLA)

1.060 +0.040 (+3.92%)
Streaming Delayed Price Updated: 10:26 AM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Estrella Immunopharma, Inc. - Common Stock

BioMedNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
From Estrella Immunopharma
Via Business Wire
News headline image
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
From Estrella Immunopharma, Inc.
Via Business Wire
BioMedNewsBreaks – Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) Starts Trading After TradeUP Acquisition Corp., Estrella Biopharma Inc. Business Combination
Via Investor Brand Network
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.